{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T01:32:50Z","timestamp":1781659970511,"version":"3.54.5"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2017,11,27]],"date-time":"2017-11-27T00:00:00Z","timestamp":1511740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,11,27]],"date-time":"2017-11-27T00:00:00Z","timestamp":1511740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Relapsed acute myeloid leukemia (AML) is a significant challenge after allogeneic hematopoietic cell transplant (HCT). Multiparameter flow cytometry (MFC), conventional cytogenetics (CG), and fluorescence in situ hybridization (FISH) are routinely performed on bone marrow specimens prior to HCT to assess disease status. We questioned the extent by which pre-HCT evidence of minimal residual disease (MRD) detected by these standard assays, corresponded with post-HCT relapse. We conducted a single center, retrospective study of 166 AML patients who underwent HCT. Thirty-eight of one hundred sixty-six (23%) patients in complete remission (CR) or CR with incomplete count recovery (CRi) had MRD detectable by MFC, CG, or FISH. MRD was more frequently seen in patients with poor risk karyotype at diagnosis (<jats:italic>P<\/jats:italic>\u2009=\u20090.011). MRD-negative patients (MRD<jats:sup>neg<\/jats:sup>) had significantly longer overall survival (OS) and relapse-free survival than patients who were MRD positive (MRD<jats:sup>pos<\/jats:sup>) (<jats:italic>P<\/jats:italic>\u2009=\u20090.002 and 0.013, respectively). In patients with MRD<jats:sup>pos<\/jats:sup> prior to HCT, the presence of acute graft vs. host disease (GVHD) (grade\u2009\u2265\u20092) or chronic GVHD significantly improved progression free survival (PFS)\u00a0(hazard ratio (HR)\u2009=\u20090.053 (95% confidence interval (CI): 0.01\u20130.279), <jats:italic>P<\/jats:italic>\u2009=\u20090.0005) and OS (HR\u2009=\u20090.211 (95% CI: 0.081\u20130.547), <jats:italic>P<\/jats:italic>\u2009=\u20090.0014).<\/jats:p>","DOI":"10.1038\/s41408-017-0007-x","type":"journal-article","created":{"date-parts":[[2017,11,23]],"date-time":"2017-11-23T10:30:28Z","timestamp":1511433028000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Minimal residual disease by either flow cytometry or cytogenetics prior to an allogeneic hematopoietic stem cell transplant is associated with poor outcome in acute myeloid leukemia"],"prefix":"10.1038","volume":"7","author":[{"given":"Maxim","family":"Norkin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmikanth","family":"Katragadda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sican","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myron","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfeng","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack W.","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan S.","family":"Moreb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Leather","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemant S.","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nosha","family":"Farhadfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1916-6276","authenticated-orcid":false,"given":"Robert","family":"Hromas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randy A.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Cogle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Wingard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,27]]},"reference":[{"key":"7_CR1","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/S0140-6736(12)61727-9","volume":"381","author":"F Ferrara","year":"2013","unstructured":"Ferrara, F. & Schiffer, C. A. Acute myeloid leukaemia in adults. Lancet \n                           381, 484\u2013495 (2013).","journal-title":"Lancet"},{"key":"7_CR2","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1001\/jamaoncol.2015.0617","volume":"1","author":"TM Kadia","year":"2015","unstructured":"Kadia, T. M., Ravandi, F., Cortes, J. & Kantarjian, H. Toward individualized therapy in acute myeloid leukemia: a contemporary review. JAMA Oncol. \n                           1, 820\u2013828 (2015).","journal-title":"JAMA Oncol."},{"key":"7_CR3","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.beha.2013.10.005","volume":"26","author":"F Ravandi","year":"2013","unstructured":"Ravandi, F. Relapsed acute myeloid leukemia: why is there no standard of care? Best Pract. Res. Clin. Haematol. \n                           26, 253\u2013259 (2013).","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"7_CR4","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1200\/JCO.2015.63.3826","volume":"34","author":"D Araki","year":"2016","unstructured":"Araki, D. et al. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission? J. Clin. Oncol. \n                           34, 329\u2013336 (2016).","journal-title":"J. Clin. Oncol."},{"key":"7_CR5","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/leu.2014.173","volume":"29","author":"RB Walter","year":"2015","unstructured":"Walter, R. B. et al. Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation. Leukemia \n                           29, 137\u2013144 (2015).","journal-title":"Leukemia"},{"key":"7_CR6","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1038\/leu.2016.46","volume":"30","author":"Y Zhou","year":"2016","unstructured":"Zhou, Y. et al. Pre- and post-transplant quantification of measurable (\u2018minimal\u2019) residual disease via multiparameter flow cytometry in adult acute myeloid leukemia. Leukemia \n                           30, 1456\u20131464 (2016).","journal-title":"Leukemia"},{"key":"7_CR7","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1200\/JCO.2010.34.2873","volume":"29","author":"Y Chen","year":"2011","unstructured":"Chen, Y. et al. Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation. J. Clin. Oncol. \n                           29, 2507\u20132513 (2011).","journal-title":"J. Clin. Oncol."},{"key":"7_CR8","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1200\/JCO.2010.31.8121","volume":"29","author":"RB Walter","year":"2011","unstructured":"Walter, R. B. et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J. Clin. Oncol. \n                           29, 1190\u20131197 (2011).","journal-title":"J. Clin. Oncol."},{"key":"7_CR9","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3390\/cancers4020601","volume":"4","author":"RM Grubovikj","year":"2012","unstructured":"Grubovikj, R. M., Alavi, A., Koppel, A., Territo, M. & Schiller, G. J. Minimal residual disease as a predictive factor for relapse after allogeneic hematopoietic stem cell transplant in adult patients with acute myeloid leukemia in first and second complete remission. Cancers \n                           4, 601\u2013617 (2012).","journal-title":"Cancers"},{"key":"7_CR10","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.bbmt.2012.09.002","volume":"19","author":"B Oran","year":"2013","unstructured":"Oran, B. et al. Significance of persistent cytogenetic abnormalities on myeloablative allogeneic stem cell transplantation in first complete remission. Biol. Blood Marrow Transplant. \n                           19, 214\u2013220 (2013).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"7_CR11","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1182\/blood-2013-06-506725","volume":"122","author":"RB Walter","year":"2013","unstructured":"Walter, R. B. et al. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood \n                           122, 1813\u20131821 (2013).","journal-title":"Blood"},{"key":"7_CR12","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/bmt.2013.124","volume":"48","author":"C Ustun","year":"2013","unstructured":"Ustun, C. et al. Achieving stringent CR is essential before reduced-intensity conditioning allogeneic hematopoietic cell transplantation in AML. Bone Marrow Transplant. \n                           48, 1415\u20131420 (2013).","journal-title":"Bone Marrow Transplant."},{"key":"7_CR13","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1038\/sj.bmt.1700804","volume":"19","author":"D Grimwade","year":"1997","unstructured":"Grimwade, D. et al. What happens subsequently in AML when cytogenetic abnormalities persist at bone marrow harvest? Results of the 10th UK MRC AML trial. Medical research council leukaemia working parties. Bone Marrow Transplant. \n                           19, 1117\u20131123 (1997).","journal-title":"Bone Marrow Transplant."},{"key":"7_CR14","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","volume":"21","author":"BD Cheson","year":"2003","unstructured":"Cheson, B. D. et al. Revised recommendations of the International working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J. Clin. Oncol. \n                           21, 4642\u20134649 (2003).","journal-title":"J. Clin. Oncol."},{"key":"7_CR15","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/j.1600-0609.2011.01580.x","volume":"86","author":"PG Hemmati","year":"2011","unstructured":"Hemmati, P. G. et al. A modified EBMT risk score predicts the outcome of patients with acute myeloid leukemia receiving allogeneic stem cell transplants. Eur. J. Haematol. \n                           86, 305\u2013316 (2011).","journal-title":"Eur. J. Haematol."},{"key":"7_CR16","unstructured":"NCCN. Guidelines for Acute Myeloid Leukemia version 3.2017 (accessed October 2017)."},{"key":"7_CR17","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo, A. et al. Defining the intensity of conditioning regimens: working definitions. Biol. Blood Marrow Transplant. \n                           15, 1628\u20131633 (2009).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"7_CR18","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1214\/aos\/1176350951","volume":"16","author":"RJ Gray","year":"1988","unstructured":"Gray, R. J. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann. Stat. \n                           16, 1141\u20131154 (1988).","journal-title":"Ann. Stat."},{"key":"7_CR19","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine, J. P. & Gray, R. J. A proportional haxzards model for subdistribution of a competing risk. J. Am. Stat. Assoc. \n                           94, 496\u2013509 (1999).","journal-title":"J. Am. Stat. Assoc."},{"key":"7_CR20","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing, Vienna, Austria, 2015)."},{"key":"7_CR21","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1182\/blood.V90.6.2465","volume":"90","author":"JF San Miguel","year":"1997","unstructured":"San Miguel, J. F. et al. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood \n                           90, 2465\u20132470 (1997).","journal-title":"Blood"},{"key":"7_CR22","doi-asserted-by":"publisher","first-page":"4123","DOI":"10.1200\/JCO.2013.49.1753","volume":"31","author":"SD Freeman","year":"2013","unstructured":"Freeman, S. D. et al. Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. J. Clin. Oncol. \n                           31, 4123\u20134131 (2013).","journal-title":"J. Clin. Oncol."},{"key":"7_CR23","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1200\/JCO.2004.03.023","volume":"22","author":"G Marcucci","year":"2004","unstructured":"Marcucci, G. et al. Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461. J. Clin. Oncol. \n                           22, 2410\u20132418 (2004).","journal-title":"J. Clin. Oncol."},{"key":"7_CR24","doi-asserted-by":"publisher","first-page":"4944","DOI":"10.1200\/JCO.2007.15.9814","volume":"26","author":"L Maurillo","year":"2008","unstructured":"Maurillo, L. et al. Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. J. Clin. Oncol. \n                           26, 4944\u20134951 (2008).","journal-title":"J. Clin. Oncol."},{"key":"7_CR25","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1200\/JCO.2012.45.9628","volume":"31","author":"M Terwijn","year":"2013","unstructured":"Terwijn, M. et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON\/SAKK AML 42A study. J. Clin. Oncol. \n                           31, 3889\u20133897 (2013).","journal-title":"J. Clin. Oncol."},{"key":"7_CR26","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1586\/ehm.10.32","volume":"3","author":"AJ Barrett","year":"2010","unstructured":"Barrett, A. J. & Battiwalla, M. Relapse after allogeneic stem cell transplantation. Expert Rev. Hematol. \n                           3, 429\u2013441 (2010).","journal-title":"Expert Rev. Hematol."},{"key":"7_CR27","first-page":"833","volume":"91","author":"E Laane","year":"2006","unstructured":"Laane, E. et al. The effect of allogeneic stem cell transplantation on outcome in younger acute myeloid leukemia patients with minimal residual disease detected by flow cytometry at the end of post-remission chemotherapy. Haematologica \n                           91, 833\u2013836 (2006).","journal-title":"Haematologica"},{"key":"7_CR28","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/bmt.2014.9","volume":"49","author":"C Anthias","year":"2014","unstructured":"Anthias, C. et al. Pre-transplant MRD predicts outcome following reduced-intensity and myeloablative allogeneic hemopoietic SCT in AML. Bone Marrow Transplant. \n                           49, 679\u2013683 (2014).","journal-title":"Bone Marrow Transplant."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-017-0007-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-017-0007-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-017-0007-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T17:31:17Z","timestamp":1671730277000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-017-0007-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,27]]},"references-count":28,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["7"],"URL":"https:\/\/doi.org\/10.1038\/s41408-017-0007-x","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,27]]},"assertion":[{"value":"20 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s note"}}],"article-number":"634"}}